Luana Calabrò

High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients

Mariantonia Logozzi, Angelo De Milito, Luana Lugini et al. · PLoS ONE · 2009 · 959 citations · Full text

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

Michele Maio, Arnaud Scherpereel, Luana Calabrò et al. · The Lancet Oncology · 2017 · 422 citations

Surgical Oncology, Malignant Disease, Relapsed Malignant Mesothelioma +8

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

Fabrice Barlési, Johan Vansteenkiste, David R. Spigel et al. · The Lancet Oncology · 2018 · 394 citations

Medicine, Metronomic Therapy, Clinical Trials +9

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

Luana Calabrò, Aldo Morra, Ester Fonsatti et al. · The Lancet Oncology · 2013 · 353 citations

Surgical Oncology, Malignant Disease, Medicine +5

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases

Anna Maria Di Giacomo, Riccardo Danielli, Massimo Guidoboni et al. · Cancer Immunology Immunotherapy · 2009 · 272 citations · Full text

Systemic Treatments, Tumor Immunology, Medicine +9